Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 May 15. doi: 10.1038/s41388-018-0300-6. [Epub ahead of print]

2.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
3.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R.

Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. Epub 2016 May 12.

4.

USP9X downregulation renders breast cancer cells resistant to tamoxifen.

Oosterkamp HM, Hijmans EM, Brummelkamp TR, Canisius S, Wessels LF, Zwart W, Bernards R.

Cancer Res. 2014 Jul 15;74(14):3810-20. doi: 10.1158/0008-5472.CAN-13-1960.

5.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

Cancer Cell. 2007 Oct;12(4):395-402.

6.

A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta.

Nijman SM, Hijmans EM, El Messaoudi S, van Dongen MM, Sardet C, Bernards R.

J Biol Chem. 2006 Aug 4;281(31):21582-7. Epub 2006 May 31.

7.

A functionally distinct member of the DP family of E2F subunits.

Milton A, Luoto K, Ingram L, Munro S, Logan N, Graham AL, Brummelkamp TR, Hijmans EM, Bernards R, La Thangue NB.

Oncogene. 2006 May 25;25(22):3212-8.

PMID:
16418725
8.

Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells.

Brummelkamp TR, Berns K, Hijmans EM, Mullenders J, Fabius A, Heimerikx M, Velds A, Kerkhoven RM, Madiredjo M, Bernards R, Beijersbergen RL.

Cold Spring Harb Symp Quant Biol. 2004;69:439-45. No abstract available.

PMID:
16117679
9.

PR72, a novel regulator of Wnt signaling required for Naked cuticle function.

Creyghton MP, Roël G, Eichhorn PJ, Hijmans EM, Maurer I, Destrée O, Bernards R.

Genes Dev. 2005 Feb 1;19(3):376-86.

10.

E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains.

Logan N, Delavaine L, Graham A, Reilly C, Wilson J, Brummelkamp TR, Hijmans EM, Bernards R, La Thangue NB.

Oncogene. 2004 Jul 1;23(30):5138-50.

PMID:
15133492
11.

A large-scale RNAi screen in human cells identifies new components of the p53 pathway.

Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R.

Nature. 2004 Mar 25;428(6981):431-7.

PMID:
15042092
12.

A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts.

Berns K, Hijmans EM, Koh E, Daley GQ, Bernards R.

Oncogene. 2000 Jul 6;19(29):3330-4.

13.
14.

Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1.

Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R.

Genes Dev. 1998 Nov 15;12(22):3488-98.

15.
16.

mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect.

Hateboer G, Hijmans EM, Nooij JB, Schlenker S, Jentsch S, Bernards R.

J Biol Chem. 1996 Oct 18;271(42):25906-11.

17.

Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.

Smith-Sørensen B, Hijmans EM, Beijersbergen RL, Bernards R.

J Biol Chem. 1996 Mar 8;271(10):5513-8.

18.

Molecular and functional characterisation of E2F-5, a new member of the E2F family.

Buck V, Allen KE, Sørensen T, Bybee A, Hijmans EM, Voorhoeve PM, Bernards R, La Thangue NB.

Oncogene. 1995 Jul 6;11(1):31-8.

PMID:
7542760
19.

E2F-5, a new E2F family member that interacts with p130 in vivo.

Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R.

Mol Cell Biol. 1995 Jun;15(6):3082-9.

20.

Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation.

Beijersbergen RL, Hijmans EM, Zhu L, Bernards R.

EMBO J. 1994 Sep 1;13(17):4080-6.

Supplemental Content

Loading ...
Support Center